ARAP2

Across TCGA pan-cancer cohorts, ARAP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARAP2 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARAP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARAP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where ARAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.317	0.712	.002	24	view →
GBM	DFS	Median	All	0.250	0.488	.006	8	view →
HNSC	OS	Tertile	All	0.935	0.831	.028	7	view →
CCRCC	DFS	Median	All	0.891	0.584	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARAP2–PDAC (DFS)

Open the PDAC breakdown →